Peer-reviewedLicence not statedFuture Oncology1 Oct 2026

DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma

Fan Yang¹
Weikang Tao²
Zihang Zhong¹
Jia Fan³
Hao Yu¹
Shukui Qin^1,4

4 affiliations

¹School of Public Health, Nanjing Medical University, Nanjing, P.R. China
²Medical Research Department, Qilu Pharmaceuticals, Global Research and Development of Innovative Medicine, Shanghai, P.R. China
³Liver Cancer Research Institute, Shanghai Zhongshan Hospital Affiliated to Fudan University, Shanghai, P.R. China
⁴TsientTang Institute for Advanced Study, Hangzhou, P.R. China

Read full text DOI Cite

ABT score based clinical model predicts prognosis in unresectable hepatocellular carcinoma treated with TACE combined with bevacizumab and sintilimab therapy
Minjun Liao, Xiaoxiao Wang, Zilong Wang +8
Frontiers in Pharmacology23 Oct 2026Peer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefDOAJ
Efficacy and safety of sintilimab plus bevacizumab with or without transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score-matched retrospective cohort study
Zizhuo Wang, Bailu Wu, Chunshu Wu +7
Frontiers in Immunology26 Oct 2026Peer-reviewedCC BY 4.0Full textImmunology General medicineCrossrefDOAJ
Early antibiotic exposure, but not late exposure, negatively affects the clinical outcomes of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
Aryoung Kim, Myung Ji Goh, Byeong Geun Song +6
Scientific Reports21 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
Acute colonic variceal bleeding treated with coil-assisted retrograde transvenous obliteration following atezolizumab-bevacizumab therapy for advanced hepatocellular carcinoma: A case report.
Sung Eun Park, Hyeon Uk Kwon, Sa Hong Jo +8
Medicine1 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort
Richard Phillips, Harry Daniels, Marie Quinlan +10
BMC Cancer1 Jul 2026Peer-reviewedCC BYFull textOncologyDOAJ

Cite

BibTeX RIS

BibTeX

@article{yang2026dubheh308,
  title = {{DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma}},
  author = {Fan Yang and Weikang Tao and Zihang Zhong and Jia Fan and Hao Yu and Shukui Qin},
  journal = {Future Oncology},
  year = {2026},
  month = oct,
  doi = {10.1080/14796694.2026.2739789},
  url = {https://doi.org/10.1080/14796694.2026.2739789},
}

RIS

TY  - JOUR
TI  - DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma
AU  - Fan Yang
AU  - Weikang Tao
AU  - Zihang Zhong
AU  - Jia Fan
AU  - Hao Yu
AU  - Shukui Qin
PY  - 2026
DA  - 2026/10/01
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2739789
UR  - https://doi.org/10.1080/14796694.2026.2739789
SN  - 1479-6694
SN  - 1744-8301
ER  -

Related

Cite